Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Does the Forecast Indicate for the Specialty Generics Market From 2025 to 2029?

The size of the specialty generics market has seen a swift expansion in the last few years. From $95.87 billion in 2024, it is predicted to advance to $107.14 billion in 2025 with a compound annual growth rate (CAGR) of 11.7%. Factors that contributed to growth during the historic period include the expiration of patents for brand-name drugs, an escalating demand for affordable substitutes, regulatory encouragement for the approval of generic drugs, rising pressures of healthcare costs, an increase in chronic illnesses, and a growing aging populace.

The market size for specialty generics is projected to experience a significant increase in the coming years, growing to “$185.68 billion in 2029 with a 14.7% compound annual growth rate (CAGR). Several factors such as the growth of the biosimilars market, emphasis on the development of complex generic drugs, increasing concentration on specialty generic injectables, the use of 3D printing in specialty generic manufacturing, and the expansion of specialty generics in emerging markets all contribute to the growth projected for this period. Noteworthy trends forecasted for this period include the increased personalization and targeting of specialty generics, strategic alliances, and collaborations in generic drug development, focus on creating abuse-deterrent formulations, incorporation of digital health technologies in specialty generics and regulatory measures aimed at fast-tracking the approval of complex generics.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7781&type=smp

What Elements Are Contributing To Growth In The Specialty Generics Market?

The rise in chronic illnesses is anticipated to boost the demand in the specialty generic market. These persistent diseases, often incurable, can sometimes be managed or even cured. The shift in lifestyle, dietary habits, and lack of weight management are often to blame for chronic health conditions, and some prolonged chronic infections can lead to a higher risk of cancer. As people become more susceptible to these illnesses, there is an increased need for specialty generic treatments to manage complex chronic diseases. For example, the World Health Organization, a UN-specialized agency based in Switzerland, reported in September 2022 that every year, globally, there were 41 million deaths, accounting for 74% of all deaths caused by non-communicable diseases or chronic diseases. The breakdown included 17.9 million deaths from heart-related diseases, 9.3 million deaths from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Thus, the rise in chronic illnesses is fueling growth in the specialty generic market.

Which Segments Are Detailed In The Global Specialty Generics Market Report?

The specialty generics market covered in this report is segmented –

1) By Route Of Administration: Injectables, Oral, Other Route Of Administration

2) By Indication: Oncology, Autoimmune Diseases, Infectious Diseases, Other Indication

3) By Distribution Channel: Retail Pharmacies, Specialty Pharmacies, Hospital Pharmaciesx

Subsegments:

1) By Injectables: Intravenous (IV) Injectables, Intramuscular (IM) Injectables, Subcutaneous (SC) Injectables

2) By Oral: Tablets, Capsules, Liquid Formulations

3) By Other Route Of Administration: Topical, Transdermal, Inhalation

What Notable Trends Are Shaping The Direction Of The Specialty Generics Market?

Prominent players in the specialty generic market, like Lisdexamfetamine Dimesylate, are getting approved to fulfill the urgent demand for medication. Specialty generics approvals denote the official license given to pharmaceutical products that are bioequivalent and therapeutically the same as original brand specialty drugs, mainly used for treating complex or rare disorders, after their patent protection has lapsed. For example, Mallinckrodt plc, a specialty pharmaceutical firm located in Ireland, obtained FDA’s approval for its Lisdexamfetamine Dimesylate Capsules under its SpecGx LLC Specialty Generics division in August 2023. These are intended to handle Attention-Deficit/Hyperactivity Disorder (ADHD). Lisdexamfetamine Dimesylate is a specialty generic and a federally controlled substance (CII), used in treating ADHD, among other conditions.

Who Are The Key Contributors To Growth In The Specialty Generics Market?

Major companies operating in the specialty generics market include Teva Pharmaceutical Industries Ltd., Endo International plc, Akorn Operating Company LLC, Mallinckrodt Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Fresenius Kabi Brasil Ltda, STADA Arzneimittel AG, Cipla Limited, Lupin Ltd, Aurobindo Pharma Limited, Aspen Pharmacare Holdings Limited, Pfizer Inc., Accord Healthcare Limited, Amneal Pharmaceuticals Inc., Sandoz International GmbH, Zydus Lifesciences Ltd., Torrent Pharmaceuticals Ltd., Perrigo Company plc, Impax Laboratories Inc., Par Pharmaceutical Companies Inc., Alvogen, Alkem Laboratories Ltd., Wockhardt Ltd., Strides Pharma Science Limited, Indoco Remedies Ltd., Unichem Laboratories Ltd., Alembic Pharmaceuticals Ltd., Jubilant Life Sciences Ltd.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/specialty-generics-global-market-report

Which Region Is Projected To Lead The Specialty Generics Market By 2025?

North America was the largest region in the specialty generics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the specialty generics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=7781&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model